Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Elective combined electroconvulsive and clozapine therapy.

D V James1, N S Gray

  • 1Department of Psychiatry and Behavioural Science, Royal Free and University College Medical School, London, UK. david.james@cableinet.co.uk

International Clinical Psychopharmacology
|April 29, 1999
PubMed
Summary

This study combined clozapine and electroconvulsive therapy (ECT) for treatment-resistant schizophrenia, showing rapid improvement and sustained compliance. This combined approach offers a viable strategy for severely disturbed patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

Leukemia·2026
Same author

Targeting chronic myeloid leukemia stem cells with ERK5 pathway inhibitors.

Journal of biological regulators and homeostatic agents·2019
Same author

c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.

Oncogene·2016
Same author

Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.

Leukemia·2016
Same author

ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.

Oncogene·2015
Same author

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

Leukemia·2015

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Clozapine therapy is essential for treatment-resistant schizophrenia but may be delayed by patient non-compliance.
  • Electroconvulsive therapy (ECT) offers rapid behavioral control but its effects are temporary.
  • Severely disturbed patients often refuse essential treatment adherence, such as blood draws for monitoring.

Purpose of the Study:

  • To investigate the efficacy and safety of a combined clozapine and ECT strategy.
  • To assess if this combined therapy can overcome treatment barriers in non-compliant patients.
  • To determine if the benefits of combined therapy persist after ECT cessation.

Main Methods:

  • Six patients with treatment-resistant schizophrenia received 12 ECT sessions over 6 weeks.

Related Experiment Videos

  • Clozapine was initiated on day 6, with blood drawn during the first anesthetic for monitoring.
  • Patient compliance with blood tests and oral medication was assessed.

    • Main Results:

    • A mean 32% improvement in Brief Psychiatric Rating Scale scores was observed by week 6.
    • Treatment adherence improved, with all patients compliant with blood tests and tablet-taking by ECT cessation.
    • No adverse reactions were noted from the combined clozapine and ECT therapy.

    Conclusions:

    • Elective combined clozapine and ECT therapy is a potentially useful strategy for treatment-resistant schizophrenia.
    • This approach may be particularly beneficial for patients requiring rapid response and those who refuse monitoring.
    • Further research into a possible synergistic effect between clozapine and ECT is warranted.